In experimental models of acute lung injury (ALI), tetracycline significantly diminished lung injury and pulmonary inflammation by selectively inhibiting caspase-1-dependent IL-1ß and IL-18 production, leading to improved survival rates. Here, IL18 is linked to acute respiratory distress syndrome.